Clinical significance of serum prostate specific antigen inprostatic cancer / 대한비뇨기과학회지

ABSTRACT

We studied the usefulness of prostate specific antigen (PSA) as well as prostatic acid phosphatase (PAP) as marker of prostatic cancer in twelve cases of advanced prostatic cancer including 4 or stage C and 8 of stage D, 50 cases of benign prostatic hyperplasia (BPH) and 50 cases of nonprostatic diseases as normal control. The positive rates of PSA were 100% for prostatic cancer, 20% for BPH and O% for nonprostatic diseases, and those of PAP were 75% for prostate cancer, 8% for BPH and 2% for nonprostatic diseases. These results indicated hat PSA is more sensitive than PAP but less specific than PAP in diagnosis of prostatic cancer. Serum PSP level was correlated with the weight of prostate in BPH patients. Serum PSA level determined during the follow-up after endocrine therapy for prostatic cancer reflected the clinical course of the patients. Because of its relatively low specificity, PSA alone may not be useful for early diagnosis of prostatic cancer. If in combination with other diagnostic modalities, it may be useful in early diagnosis and therapeutic monitoring of prostatic cancer within restricted limits.